187 related articles for article (PubMed ID: 33373589)
81. Feasibility of endoscopic mucosal resection as salvage treatment for patients with local failure after definitive chemoradiotherapy for stage IB, II, and III esophageal squamous cell cancer.
Makazu M; Kato K; Takisawa H; Yoshinaga S; Oda I; Saito Y; Mayahara H; Ito Y; Itami J; Hamaguchi T; Yamada Y; Shimada Y
Dis Esophagus; 2014 Jan; 27(1):42-9. PubMed ID: 23442160
[TBL] [Abstract][Full Text] [Related]
82. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer.
Jung HA; Noh JM; Sun JM; Lee SH; Ahn JS; Ahn MJ; Pyo H; Ahn YC; Park K
Lung Cancer; 2020 Aug; 146():23-29. PubMed ID: 32505077
[TBL] [Abstract][Full Text] [Related]
83. Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC.
Amino Y; Kitazono S; Uematsu S; Hasegawa T; Yoshizawa T; Uchibori K; Yanagitani N; Horiike A; Horai T; Kasahara K; Nishio M
Int J Clin Oncol; 2020 Jan; 25(1):67-73. PubMed ID: 31506751
[TBL] [Abstract][Full Text] [Related]
84. Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer.
Hamada A; Soh J; Mitsudomi T
Transl Lung Cancer Res; 2021 Jan; 10(1):555-562. PubMed ID: 33569336
[TBL] [Abstract][Full Text] [Related]
85. Surgery after chemoradiotherapy in patients with stage III (N2 or N3, excluding T4) non-small-cell lung cancer: a systematic review.
Swaminath A; Vella ET; Ramchandar K; Robinson A; Simone C; Sun A; Ung YC; Yasufuku K; Ellis PM
Curr Oncol; 2019 Jun; 26(3):e398-e404. PubMed ID: 31285684
[TBL] [Abstract][Full Text] [Related]
86. [Induction Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer].
Miura A; Soh J; Shien K; Yamamoto H; Toyooka S
Kyobu Geka; 2018 Apr; 71(4):270-277. PubMed ID: 29755100
[TBL] [Abstract][Full Text] [Related]
87. Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials.
Honglian M; Zhouguang H; Fang P; Lujun Z; Dongming L; Yujin X; Yong B; Liming X; Yirui Z; Xiao H; Jin W; Yue K; Lvhua W; Ming C
Thorac Cancer; 2020 Apr; 11(4):898-906. PubMed ID: 32068962
[TBL] [Abstract][Full Text] [Related]
88. The impact of epidermal growth factor receptor mutations on the efficacy of definitive chemoradiotherapy in patients with locally advanced unresectable stage III non-small cell lung cancer: a systematic review and meta-analysis.
Qin Q; Peng B; Li B
Expert Rev Anticancer Ther; 2019 Jun; 19(6):533-539. PubMed ID: 31104529
[No Abstract] [Full Text] [Related]
89. Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer.
Roengvoraphoj O; Wijaya C; Eze C; Li M; Dantes M; Taugner J; Tufman A; Huber RM; Belka C; Manapov F
Strahlenther Onkol; 2018 Feb; 194(2):107-115. PubMed ID: 29116336
[TBL] [Abstract][Full Text] [Related]
90. Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer.
Lan WG; Hao YZ; Xu DH; Wang P; Zhou YL; Ma LB
Clin Transl Oncol; 2016 Apr; 18(4):375-80. PubMed ID: 26329292
[TBL] [Abstract][Full Text] [Related]
91. Definitive Chemoradiotherapy for Advanced Pulmonary Sarcomatoid Carcinoma.
Takeda K; Matsushita H; Kubozono M; Tanabe T; Ishikawa Y; Yamamoto T; Kozumi M; Takahashi N; Katagiri Y; Tasaka S; Fukui K; Takeda K; Fujishima F; Ichinose M; Jingu K
Intern Med; 2016; 55(22):3325-3330. PubMed ID: 27853077
[TBL] [Abstract][Full Text] [Related]
92. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
[TBL] [Abstract][Full Text] [Related]
93. Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP).
Faehling M; Schumann C; Christopoulos P; Hoffknecht P; Alt J; Horn M; Eisenmann S; Schlenska-Lange A; Schütt P; Steger F; Brückl WM; Christoph DC
Lung Cancer; 2020 Dec; 150():114-122. PubMed ID: 33126091
[TBL] [Abstract][Full Text] [Related]
94. Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer.
Cardenal F; Arnaiz MD; Morán T; Jové J; Nadal E; Porta R; Solé JM; Brao I; Palmero R; Fuentes R; Núñez I; Caveda E; Cassinello A
Lung Cancer; 2011 Oct; 74(1):69-74. PubMed ID: 21353323
[TBL] [Abstract][Full Text] [Related]
95. Blood Parameters Demonstrating a Significant Survival Impact in Patients With Locally Advanced NSCLC Undergoing Definitive Chemoradiotherapy.
Hoffmann M; Reitz D; Taugner J; Roengvoraphoj O; Käsmann L; Eze C; Karin M; Belka C; Manapov F
Anticancer Res; 2020 Apr; 40(4):2319-2322. PubMed ID: 32234932
[TBL] [Abstract][Full Text] [Related]
96. Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non-small cell lung cancer.
Topkan E; Selek U; Ozdemir Y; Yildirim BA; Guler OC; Mertsoylu H; Hahn SM
Lung Cancer; 2018 Jul; 121():30-36. PubMed ID: 29858023
[TBL] [Abstract][Full Text] [Related]
97. Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment.
Käsmann L; Taugner J; Eze C; Roengvoraphoj O; Dantes M; Gennen K; Karin M; Petrukhnov O; Tufman A; Belka C; Manapov F
Anticancer Res; 2019 Sep; 39(9):5077-5081. PubMed ID: 31519618
[TBL] [Abstract][Full Text] [Related]
98. Updated long-term outcomes of salvage surgery after stereotactic body radiotherapy for early-stage non-small-cell lung cancer.
Yamanashi K; Hamaji M; Matsuo Y; Kishi N; Chen-Yoshikawa TF; Mizowaki T; Date H
Interact Cardiovasc Thorac Surg; 2020 Dec; 31(6):892-894. PubMed ID: 32974674
[TBL] [Abstract][Full Text] [Related]
99. Tumour response in non-small-cell lung cancer patients treated with chemoradiotherapy - Can spectral CT predict recurrence?
Fehrenbach U; Feldhaus F; Kahn J; Böning G; Maurer MH; Renz D; Frost N; Streitparth F
J Med Imaging Radiat Oncol; 2019 Oct; 63(5):641-649. PubMed ID: 31282130
[TBL] [Abstract][Full Text] [Related]
100. Superior Treatment Response and In-field Tumor Control in Epidermal Growth Factor Receptor-mutant Genotype of Stage III Nonsquamous Non-Small cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy.
Lim YJ; Chang JH; Kim HJ; Keam B; Kim TM; Kim DW; Paeng JC; Kang KW; Chung JK; Jeon YK; Chung DH; Wu HG
Clin Lung Cancer; 2017 May; 18(3):e169-e178. PubMed ID: 28131636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
